- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
Source: The post is based on the article “DRDO-developed technology behind critical drug approved by DCGI for radiological and nuclear emergencies” published in The Hindu on 16th March 2023
What is the News?
The Defence Ministry has announced that the Prussian blue insoluble formulations drug has been granted approval by the Drugs Controller General of India(DCGI).
What is a Prussian blue insoluble formulation drug?
It is one of the critical medicines listed by the World Health Organisation(WHO) for radiological and nuclear emergencies.
It is used to treat the symptoms of Cesium or Thallium Contamination.
The drug was developed under the Technology Development Fund(TDF).
The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
